Wobble Genomics, a groundbreaking spin-out from the University of Edinburgh, has announced securing £8.5M (approximately €9.93M) in a new funding round. Specializing in enhancing RNA and DNA sequencing efficiency, the company is set to revolutionize the identification and detection of nucleic acid biomarkers with this significant investment.
The funding round, led by Mercia Ventures and BGF, with support from IQ Capital, EOS Advisors, and Old College Capital (the university’s venture fund), brings Wobble Genomics’ total raised capital to over £10.5M (approximately €12.27M). Operating in stealth mode, Wobble Genomics has developed a method to detect previously unseen ‘full length’ RNA, promising applications across drug development, research, agriculture, and ecology.
Advertisement
Overcoming Traditional RNA Sequencing Challenges
Wobble Genomics’ approach enables long-read sequencing, overcoming traditional RNA sequencing challenges related to instability and complexity. This advancement captures full-length RNA for more comprehensive applications, offering valuable insights for research and various applications.
Founded by Experts in Long-Read RNA Sequencing
Founded in 2021 by Dr. Richard Kuo, with over 15 years of expertise in biology and bioengineering, Wobble Genomics is poised for growth. The company, currently with a team of 10, plans to double in size over the next two years, leveraging its innovative technology for commercialization.
Utilizing Capital for Commercialization and Expansion
The funding will support the commercialization of Wobble Genomics’ RNA sequencing technology. Dr. Kuo highlighted the shift towards long-read RNA sequencing as one of the most exciting developments in biotechnology, aiming to accelerate a new wave of innovations.
Backed by Leading Life Science Investors
Mercia Ventures and BGF, along with other investors, have shown strong support for Wobble Genomics’ potential to revolutionize genetic sequencing. Lee Lindley of Mercia Ventures praised the technology’s far-reaching applications, including precision medicine, while Jo Smart of BGF emphasized the potential in revolutionizing early cancer marker detection.
With this funding, the startup is set to pursue its mission to reveal the unseen world of RNA, unlocking exciting new applications and contributing to the advancement of genetic sequencing technology.
